How the RSV Vaccine (Arexvy) Works

The first vaccine targeting respiratory syncytial virus (RSV) was just approved for use in the United States. The vaccine is made by GSK, under the name Arexvy, and is for use in individuals 60 years of age+. Older adults are at particular risk for severe disease and death caused by RSV. This approval highlights a critical milestone in public health efforts to combat the prevention of lower respiratory tract disease.

[@marusholilac]

When I searched for info on this vaccine, I had to skip past a LOT of KZbin suggestions showing broadcast TV stories and even a Walgreens promo, to find a video I could trust. I just assumed the TV stories were going to be written by the pharmaceutical company. Now I know there is no way to know how long this vaccine will be effective, but I'm going to make a guess that it's going to be good for only 1 season, meaning it could be a cash cow. I'd also like to learn how much it will cost, even though I may not have to bear this cost directly. I'm 78 and I'm happy to get any vaccine I'm offered, after I do my due diligence to be sure there are no "gotchas".

[@nickturnock3369]

Yes. most respitory viruses infect us multile times over our lives so the vaccines won't give long term protection. Having survived infancy, about 1% of us would die from RSV if unvaccinated.

[@atg4469]

Do you have a link to the study? Also was there a study done in babies?

[@KarinLynnBates]

This is exciting! For a long time RSV has caused babies and older people to be under a lot of risk. What great news!

[@ScientistSwanda]

yes exactly! let’s hope this approval can extend into other vulnerable populations soon 🙏

[@jimmyzoom1143]

The amish just laugh at us